Search Results
Mar 16, 2026, 08:00 ET Argo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE
prekallikrein (PKK), a well-validated target for hereditary angioedema (HAE) treatment, offering the possibility of prevention of HAE attacks with a long-term effect. Argo Biopharma is currently conducting a global Phase II study in adult HAE patients. The Company anticipates primary completion of the Phase
More news about: Argo Biopharmaceutical Co., Ltd
Mar 09, 2026, 11:01 ET CSL announces expansion of Illinois plasma therapy manufacturing facility
relatively rare but together, they affect thousands of people, including those living with hemophilia, primary immunodeficiency, and hereditary angioedema (HAE). In addition to treating rare conditions, PDTs are also used as a lifesaving standard of care for many emergency and life-threatening conditions. These
More news about: CSL
Feb 25, 2026, 21:00 ET Argo Biopharma to Present Positive Phase II Interim Results of siRNA Therapeutic BW-20805 for HAE at the 2026 AAAAI Annual Meeting
favorable safety and tolerability profile, supporting its potential as a long-acting prophylactic therapy for HAE.About Hereditary Angioedema (HAE)Hereditary angioedema (HAE) is a rare genetic condition that causes sudden and unpredictable swelling in different parts of the body.
More news about: Argo Biopharmaceutical Co., Ltd
Feb 23, 2026, 16:15 ET Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug
More news about: Haemonetics Corporation
Feb 20, 2026, 16:05 ET Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors
More news about: Haemonetics Corporation
Feb 05, 2026, 06:00 ET Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
onlineBOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations
More news about: Haemonetics Corporation
Jan 20, 2026, 21:00 ET Produk Lensa Kontak dan Perawatan Lensa CLEARLAB Raih Sertifikasi Gabungan MDSAP, ISO 13485, dan EU MDR dari DNV
produsen alat kesehatan yang menghadapi lanskap regulasi yang semakin kompleks, sambil tetap menjaga standar kualitas produk dan keselamatan pasien," ujar Hae Kyeung Park, Managing Director, Clearlab."Produsen alat kesehatan inovatif berhadapan dengan banyak tantangan besar. Salah satunya, proses
More news about: DNV
Jan 20, 2026, 21:00 ET CÁC SẢN PHẨM KÍNH ÁP TRÒNG VÀ DUNG DỊCH CHĂM SÓC KÍNH CỦA CLEARLAB ĐẠT CHỨNG NHẬN MDSAP, ISO 13485 VÀ EU MDR TỪ DNV
tế định hướng trong bối cảnh quy định ngày càng phức tạp, đồng thời vẫn duy trì tiêu chuẩn cao về chất lượng sản phẩm và an toàn cho người bệnh", bà Hae Kyeung Park, Giám đốc điều hành của Clearlab cho biết."Một trong những thách thức lớn nhất đối với các nhà sản xuất thiết bị y tế đổi mới phải
More news about: DNV
Jan 12, 2026, 01:48 ET EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure, through a sale to Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes. Vivasure's PerQseal® Elite
More news about: EQT
Jan 09, 2026, 06:15 ET Haemonetics Acquires Vivasure Medical Limited
BOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition
More news about: Haemonetics Corporation
Jan 07, 2026, 18:17 ET Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026
BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, February 5, 2026. The Company
More news about: Haemonetics Corporation
Jan 02, 2026, 06:00 ET Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January
More news about: Haemonetics Corporation
Dec 16, 2025, 02:49 ET Madame Tussauds Hong Kong Sambut Kehadiran Bintang "K-Wave" Baru Lewat Peluncuran Patung Lilin Perdana Jung Hae In
memperkenalkan patung lilin aktor Korea ternama Jung Hae In pada hari ini. Sebagai koleksi terbaru yang hadir di K-Wave Zone, patung lilin pertama dari Jung Hae In mengajak para pengunjung dari seluruh dunia untuk memasuki drama Korea romantis. Jung Hae In secara langsung meresmikan patung lilin ini,
More news about: Madame Tussauds Hong Kong
Dec 16, 2025, 02:30 ET Madame Tussauds Hong Kong chào đón ngôi sao K-Wave mới, tượng sáp đầu tiên của Jung Hae In ra mắt
nam thần màn ảnh Hàn Quốc Jung Hae In hôm nay. Là sự bổ sung mới nhất cho Khu vực K-Wave nổi bật, tượng sáp đầu tiên của Jung Hae In mời gọi du khách từ khắp nơi trên thế giới bước vào thế giới đầy mê hoặc của những bộ phim truyền hình Hàn Quốc lãng mạn. Jung Hae In đã trực tiếp ra mắt bản sao
More news about: Madame Tussauds Hong Kong
Nov 28, 2025, 08:14 ET Dunamu - Team NAVER, Declare Global Lead with Mega Synergy of AI and Web3
The press conference was attended by NAVER Founder and Global Investment Officer Hae-jin Lee, Dunamu Chairman Chi-hyung Song, NAVER CEO Soo Yeon Choi, Dunamu CEO Kyung-seok Oh and NAVER Financial CEO Sang-jin Park.Dunamu operating
More news about: Dunamu
Nov 19, 2025, 17:31 ET KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
treatment of HAE. The objective with navenibart is to deliver fast-acting and long-lasting prevention of HAE attacks through a well-established mechanism and trusted antibody modality, administered subcutaneously every 3 to 6 months. The ultimate goal is to enable people living with HAE to lead lives
More news about: DelveInsight Business Research, LLP
Nov 06, 2025, 21:00 ET Argo Biopharma to Present Positive Phase I Results of siRNA Therapeutic BW-20805 for HAE at ACAAI 2025
as a potential long-acting and effective therapy for people living with HAE." About Hereditary Angioedema (HAE) Hereditary angioedema (HAE) is a rare genetic condition that causes sudden and unpredictable swelling
More news about: Argo Biopharmaceutical Co., Ltd
Nov 06, 2025, 06:00 ET Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the Company's Investor Relations
More news about: Haemonetics Corporation
Oct 09, 2025, 16:05 ET Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025
BOSTON, Oct. 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, November 6, 2025. The Company
More news about: Haemonetics Corporation
Oct 02, 2025, 08:00 ET CODIT Policy Institute Releases Issue Paper on U.S. 50% Tariffs on Aluminum and Copper, Urges Korea's Strategic Response
Korea, Oct. 2, 2025 /PRNewswire/ -- The CODIT Global Evidence-Based Policy Institute (Executive Director Hae-young Song), the research arm of AI-powered policy platform CODIT, today released an issue paper titled "U.S. Imposes 50% Tariffs on Aluminum and
More news about: CODIT Corp.
Sep 14, 2025, 20:30 ET Hugel hosts global H.E.L.F. symposium, marking 15 years of botulinum toxin Letybo
to the Future of Aesthetics," highlighted the latest clinical cases and strategies using Letybo, with speakers including Dr. Hae-Jin Lee of Yonsei A&B Dermatology Clinic, Dr. Ayaka Nishikawa of Shonan Beauty Clinic, and Hosung
More news about: Hugel